Journal article
Automated seizure detection with noninvasive wearable devices: A systematic review and meta-analysis
V Naganur, S Sivathamboo, Z Chen, S Kusmakar, A Antonic-Baker, TJ O'Brien, P Kwan
Epilepsia | WILEY | Published : 2022
DOI: 10.1111/epi.17297
Abstract
Objective: This study was undertaken to review the reported performance of noninvasive wearable devices in detecting epileptic seizures and psychogenic nonepileptic seizures (PNES). Methods: We conducted a systematic review and meta-analysis of studies reported up to November 15, 2021. We included studies that used video-electroencephalographic (EEG) monitoring as the gold standard to determine the sensitivity and false alarm rate (FAR) of noninvasive wearables for automated seizure detection. Results: Twenty-eight studies met the criteria for the systematic review, of which 23 were eligible for meta-analysis. These studies (1269 patients in total, median recording time = 52.9 h per patient)..
View full abstractGrants
Awarded by UCB Pharma
Funding Acknowledgements
Z.C. is supported by an Early Career Fellowship from the National Health and Medical Research Council (GNT1156444). S.S. is supported by a Bridging Postdoctoral Fellowship from Monash University (BPF20-3253672466) and the Victorian Medical Research Acceleration Fund. She reports salary support to her institutions from Kaoskey and Optalert for clinical trial related activities; she receives no direct personal income for these activities. T.J.O. is supported by a Program Grant (APP1091593) and Investigator Grant (APP1176426) from the National Health and Medical Research Council of Australia, and the Victorian Medical Research Acceleration Fund. His institution has received research grants and consultancy funding from Eisai, UCB Pharma, LivaNova, BioGen, and Zynerba unrelated to the submitted work. P.K. is supported by a Medical Research Future Fund Practitioner Fellowship (MRF1136427). His institution has received research grants from Biscayne Pharmaceuticals, Eisai, GW Pharmaceuticals, LivaNova, Novartis, UCB Pharma, and Zynerba outside the submitted work; he has received speaker fees from Eisai, LivaNova, and UCB Pharma outside the submitted work. None of the other authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.